tiprankstipranks

CymaBay downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald downgraded CymaBay Therapeutics (CBAY) to Neutral from Overweight with a price target of $32.50, up from $30, following the announcement of its proposed acquisition by Gilead (GILD) for $32.50 per share.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on CBAY:

Disclaimer & DisclosureReport an Issue